Epidermal Growth Factor Receptor Serum Levels and Prognostic Value in Malignant Gliomas

Quaranta, Michele; Divella, Rosa; Daniele, Antonella; Tardo, Silvia Di; Venneri, Maria Teresa; Lolli, Ivan; Troccoli, G

doi:10.1177/030089160709300308

Cited by 40 publications

(31 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In contrast to a previous study [18], we were unable to detect any difference in serum EGFR levels between patients with GBM, anaplastic glioma, and healthy controls. We used the same ELISA assay as Quaranta et al, but included also anaplastic oligodendrogliomas, oligoastrocytomas, and GBMs with oligodendroglioma component.…”

Section: Serum Egfr Is Not Related To Egfr Status In the Tumor Tissuecontrasting

confidence: 99%

“…Measuring serum levels of EGFR extracellular domain (ECD) has provided additional information on tumor aggressiveness and outcome in various types of malignancies [14][15][16][17]. Quaranta et al found elevated serum EGFR levels also in patients with glioblastomas compared to anaplastic astrocytomas or controls [18]. However, the association of serum EGFR levels to EGFR overexpression and amplification status in tumor tissue or to other molecular markers has not previously been studied.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Serum levels of GFAP and EGFR in primary and recurrent high-grade gliomas: correlation to tumor volume, molecular markers, and progression-free survival

et al. 2015

View full text Add to dashboard Cite

Our aim was to study the association of two potential serum biomarkers glial fibrillary acidic protein (GFAP) and epidermal growth factor receptor (EGFR) with prognostic markers such as IDH1 mutation, tumor burden, and survival in patients with high-grade gliomas (HGG). Additionally, our objective was to evaluate the potential of serum EGFR as a surrogate marker for EGFR status in the tumor. Pre-operative serum samples were prospectively collected from patients with primary (n = 17) or recurrent (n = 10) HGG. Serum GFAP and EGFR levels were determined by ELISA and studied for correlation with molecular markers including EGFR amplification, tumor volume in contrast-enhanced T1-weighted MRI, and progression-free survival (PFS). Pre-operative serum GFAP level of ≥0.014 ng/ml was 86 % sensitive and 85 % specific for the diagnosis of glioblastoma. High GFAP was related to the lack of IDH1 mutation (P = 0.016), high Ki67 proliferation index (P < 0.001), and poor PFS (HR 5.9, CI 1.2-29.9, P = 0.032). Serum GFAP correlated with enhancing tumor volume in primary (r = 0.64 P = 0.005), but also in recurrent HGGs (r = 0.76 P = 0.011). In contrast, serum EGFR levels did not differ between HGG patients and 13 healthy controls, and were not related to EGFR status in the tumor. We conclude that high serum GFAP associates with IDH1 mutation-negative HGG, and poor PFS. Correlation with tumor burden in recurrent HGG implicates the potential of serum GFAP for detection of tumor recurrence. Our results suggest that circulating EGFR is not derived from glioma cells and cannot be used as a marker for EGFR status in the tumor.

show abstract

Section: Serum Egfr Is Not Related To Egfr Status In the Tumor Tissuecontrasting

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Serum levels of GFAP and EGFR in primary and recurrent high-grade gliomas: correlation to tumor volume, molecular markers, and progression-free survival

et al. 2015

View full text Add to dashboard Cite

show abstract

“…For example, serum-borne epidermal growth factor receptor (EGFR) levels were shown to be significantly different when comparing healthy controls with malignant glioma patients and EGFR serum levels are associated with prognosis (2). Levels of a proliferation-inducing ligand (APRIL) have been found to be elevated in the sera of glioblastoma (GBM) patients when compared to non-tumor controls (3).…”

Section: Introductionmentioning

confidence: 99%

Identification of blood protein biomarkers that aid in the clinical assessment of patients with malignant glioma

Gowda

et al. 2012

Int J Oncol

View full text Add to dashboard Cite

Abstract. Analyzing molecular biomarkers using blood is an important approach for clinical assessment of malignant glioma. We investigated a molecular proteomic biomarkerbased approach for glioblastoma using patients' blood samples. The expression levels of a list of candidate proteins were quantified in plasma and serum samples from two different cohorts of patients with malignant glioma and normal controls. The biological function was studied for one of the identified markers. Additionally, the prognostic significance of protein marker expression was measured by survival analysis. As a result, protein biomarkers associated with malignant glioma were identified from the blood specimens and five of the protein biomarkers were common to both cohorts. Immunohistochemical analysis demonstrated that many of the protein biomarkers identified in peripheral blood specimens were expressed in malignant gliomas. Staining levels for one of the biomarkers, MIP-1α, was found to correlate with WHO grade among invasive gliomas, and we demonstrate that MIP-1α promotes human glioblastoma cell proliferation and migration. Additionally, four prognostic protein biomarkers were identified. In conclusion, we demonstrate that both peripheral blood plasma and serum specimens are highly valuable and complementary to each other in the quest for protein biomarkers of malignant glioma. Sets of novel protein biomarkers were identified that may aid in the diagnosis and prognosis of patients with malignant glioma.

show abstract

“…Zhao et al data show that tumour a v b 3 integrin stands as a therapeutic target for the prevention of skeletal metastases. The nonpeptide antagonist of a v b 3 (PSK1404) showed a meaningful antitumour effects in experimental breast and ovarian cancer bone metastasis [58]. Vitaxin, an antihuman a v b 3 antibody is currently in clinical trials as a treatment for metastatic melanoma and results indicate that this drug may be instrumental in inhibiting the advancement of lifethreatening cancers [59].…”

Section: Therapeutic Targetsmentioning

confidence: 99%

Membrane and membrane‐associated proteins involved in the aggressive phenotype displayed by highly invasive cancer cells

2008

View full text Add to dashboard Cite

Invasion, the penetration of tumour cells into adjacent tissues, is a fundamental characteristic of malignant carcinomas and a first step in the metastatic process. The molecular mechanisms involved in tumour cell invasion are complex, but over the last couple of decades the knowledge base has grown quite considerably and many proteins with important roles in invasion have been identified and characterised. Benign tumours typically are encapsulated, which inhibits their ability to behave in a malignant manner, meaning these tumours do not grow in a location-limited less aggressive manner, do not invade surrounding tissues and do not metastasise. The ability of malignant tumours to invade and metastasise is the major cause of death for cancer patients. A greater insight into the molecular basis of cancer invasion and metastasis will lead to the development of novel therapies and specific panels of biomarkers for use in the treatment and diagnosis/monitoring in many types of metastatic cancer.

show abstract

Epidermal Growth Factor Receptor Serum Levels and Prognostic Value in Malignant Gliomas

Abstract: Although a prospective study with large sample size is warranted, serum EGFR extracellular domain may be potentially useful as a biological marker of gliomas for prediction of prognosis and follow-up after treatment.

Cited by 40 publications

References 27 publications

Serum levels of GFAP and EGFR in primary and recurrent high-grade gliomas: correlation to tumor volume, molecular markers, and progression-free survival

Serum levels of GFAP and EGFR in primary and recurrent high-grade gliomas: correlation to tumor volume, molecular markers, and progression-free survival

Identification of blood protein biomarkers that aid in the clinical assessment of patients with malignant glioma

Membrane and membrane‐associated proteins involved in the aggressive phenotype displayed by highly invasive cancer cells

Contact Info

Product

Resources

About